NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears
NeOnc Technologies (NASDAQ: NTHI) is poised for a major clinical catalyst with the upcoming top-line Phase 2a data announcement of their investigational drug NEO100, targeting recurrent IDH1-mutant Grade III/IV gliomas. The data readout on August 12, 2026, will reveal efficacy and safety results that could impact regulatory pathway decisions and fu…